Searching for Therapeutic Drugs that Target Causative Proteins of Alport Syndrome (IMAGE)
Caption
Collagen IV alpha-3, alpha-4, and alpha-5 in Alport Syndrome cannot form trimers so the discovery of compounds that leads to or improves their formation will lead to the development of novel therapies. New work from Kumamoto University makes it possible to evaluate the trimerization of collagen IV alpha chains by measuring luminescence. Compounds that induce luminescence in the NanoLuc-Col4 system are likely to promote trimerization.
Credit
Dr. Kohei Omachi
Usage Restrictions
These images may only be used in conjunction with the accompanying release, or stories written about the work described in the release with reference to the original work.
License
Licensed content